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HLA-DM Acts as a Molecular Chaperone and
Rescues Empty HLA-DR Molecules at Lysosomal pH
Harald Kropshofer, Sven O. Arndt, several class II alleles at endosomal pH (Urban et al.,
1994; Kropshofer et al., 1995a, 1995b), an additionalGerhard Moldenhauer, GuÈ nter J. HaÈ mmerling,
molecule, HLA-DM (DM), appears to be required for effi-and Anne B. Vogt
cient CLIP release and acquisition of cognate peptidesDepartment of Molecular Immunology
in an allele-independent manner (Morris et al., 1994;German Cancer Research Center
Fling et al., 1994). The two subunits of HLA-DM areIm Neuenheimer Feld 280
encoded within the MHC class II region (Kelly et al.,D-69120 Heidelberg
1991; Cho et al., 1991), but owing to unique characteris-Federal Republic of Germany
tics they appear to form an unconventional class II±like
heterodimer. Unlike classical class II molecules, HLA-
DM and its murine counterpart, H-2M, are barely ex-Summary
pressed at the cell surface (Sanderson et al., 1994; Karls-
son et al., 1994) owing to a cytoplasmic internalizationHLA-DM (DM) is a nonclassical MHC class II molecule
sequence (Marks et al., 1995b; Lindstedt et al., 1995).that interacts with classical MHC II molecules in acidic
Instead, HLA-DM accumulates in late endosomal/lyso-compartments. During this association DM is sup-
somal compartments of antigen-presenting cells whereposed to catalyze the release of invariant chain (Ii)-
it colocalizes with HLA-DR molecules (Sanderson et al.,derived CLIPpeptides, as well asother peptides bound
1994; Pierre et al., 1996), and where it has been foundwith low kinetic stability. Here we provide evidence
to be engaged in transient DM±DR complexes (Sand-that in lysosomal compartments of B cells a consider-
erson et al., 1996). A specific DM±DR interaction is be-able fraction of DM is stably associated with empty
lieved to be responsible for the accelerated removal ofDR ab dimers, thereby preventing their functional in-
CLIP (Sloan et al., 1995; Denzin and Cresswell, 1995;activation and aggregation. Upon encounter with cog-
Sherman et al., 1995) and leupeptin-induced precursors,nate peptide, the DM-associated DR molecules can
such as LIP (Schafer et al., 1996) or SLIP (Stebbins etbe rapidly loaded and no longer bind to DM. Thus, DM
al., 1996). Most recent studies have demonstrated thatseems to act as a dedicated class II±specific chaper-
DM catalyzes the exchange of CLIP for cognate peptideone. In view of the suggested shortage ofDM-resistant
in an enzyme-like fashion attaining turnover numbers ofself-peptides in the loading compartment,empty class
up to 12 DR±CLIP complexes per minute at endosomalII molecules that are chaperoned by DM may enable
pH (Vogt et al., 1996). This provides a rationale for thethe antigen-processing system to respond promptly
finding that DM is able to facilitate loading of class II
to the challenge by newly entering antigens.
molecules with high efficiency at substoichiometric
amounts. Moreover, there is accumulating evidence that
Introduction DM exhibits a rather broad substrate specificity and is
not restricted to class II±CLIP complexes: DM was also
Classical major histocompatibility complex (MHC) class found to release non-CLIP peptides that had bound to
II molecules are peptide receptors and specialized in the respective allele with an intrinsic low kinetic stability,
presenting self and antigenic peptides to CD41 T cells. owing to suboptimal anchor±pocket interactions or sub-
After biosynthesis, a and b chains of class II molecules optimal length (Kropshofer et al., 1996; Weber et al.,
assemble together with the invariant chain (Ii) in the 1996; van Ham et al., 1996). These findings support the
endoplasmic reticulum (ER) (Roche and Cresswell, 1990) previously raised hypothesis that DM acts as a peptide
forming a nonameric complex (Roche et al., 1991) that editor (Sloan et al., 1995). Thus, DM appears to have
is transported to the trans-Golgi network and subse- the potential to skew the peptide repertoire presented
quently sorted to endosomal/lysosomal compartments to T cells toward a population of high stability class
(Bakke and Dobberstein, 1990; Lamb et al., 1991). Ii II±peptide complexes.
associates with class II molecules by virtue of a segment After DM-mediated removal of CLIP or low stability
encoded by exon 3 and designated CLIP (class II± peptides, the groove of ab dimers is empty unless other
associated Ii peptide) (Riberdy et al., 1992; Bijlmakers peptides or unfolded polypeptides meeting the require-
et al., 1994), but regions adjacent toCLIP also contribute ments for binding are available. In case of ligand short-
to binding (Vogt et al., 1995). In acidic compartments, age empty class II dimers are likely to become function-
Ii undergoes stepwise proteolytic digestion (Maric et al., ally inactivated owing to self-aggregation, misfolding,
1994), with cathepsin S suggested to be mainly respon- or disassembly of the subunits (Germain and Rinker,
sible for the generation of CLIP (Riese et al., 1996). As 1993; Sadegh-Nasseri et al., 1994; Devaux et al., 1995).
the CLIP sequence contains a clustering of amino acid As it has been reported that the supply of self-peptides
side chains crucial for promiscuous binding to class II in the loadingcompartment may be insufficient (Germain
peptide±binding grooves (Sette et al., 1995), CLIP forms and Hendrix, 1991; Sadegh-Nasseri and Germain, 1991),
intermediate complexes with ab dimers and, therefore, the question arises how empty binding sites are chaper-
needs to be removed before loading with antigenic pep- oned to maintain the structural integrity of class II dimers
tides and exit to the cell surface can proceed (Avva and under these conditions. Here we provide evidence that
Cresswell, 1994). DM is engaged in complexes with empty class II mole-
cules in vitro as well as in vivo thereby preventing themAlthough CLIP by itself can rapidly dissociate from
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Figure 1. DM Prevents DR1 from Functional
Inactivation in the Absence of Peptide
(A) 100 nM DR1±CLIP complexes were prein-
cubated at pH 5.0 at 378C without addition of
peptide in the absence and presence of 100
or 200 nM DM for the indicated periods of
time. Subsequently, the amount of DR1 mole-
cules still functional was quantified by adding
AMCA-labeled HA peptide (5 mM) and DM
(100 nM) in those cases where DM was not
present during the preincubation (left panel).
Binding of AMCA-HA peptide was deter-
mined by HPSEC after a 3 min incubation
time. All samples were centrifuged prior to
HPSEC analysis to remove aggregates. 100%
binding represents the HA binding without
preincubation and equals about 148,000 6
15,000 fluorescence units with 100 nM DM
and about 158,000 6 18,000 fluorescence
units with 200 nM DM. After the 3 min incuba-
tion, approximately 12%±16% of the total
amount of DR1 molecules were occupied
with AMCA-HA, as determined according to
the previously described procedure (Krops-
hofer et al., 1995b). Given are representative
results of two to three experiments.
(B) DR1±CLIP (100 nM) was preincubated for
15 min with and without DM, as described
above, and then coincubated with DM (200
nM) for the indicated periods of time (0±120
min) before HA peptide was added.
(C) 100 nM DR1±CLIP complexes were prein-
cubated at pH 5.0 at 378C for 15 min in the
absence and presence of DM (100 nM), BSA
(500 nM), BSA (500 nM) together with DM (50
nM), anti-DRab MAbL243 (500 nM), or murine
class II Ak (500 nM). The amount of functional
DR1 was quantified as described above.
(D) DR1±CLIP (50 nM) was preincubated at
pH 5.0 at 378C for 15 min without or with DM
(50 nM). DM or AMCA-labeled DQSP peptide
was added during the subsequent 3 min incubation, as indicated, and the amount of functional DR1 was quantified by HPSEC, as described
for (A). 100% relative binding of AMCA-DQSP peptide obtained in two independent experiments corresponds to 186,000 6 20,000 fluorescence
units (approximately 19 6 2% overall occupancy).
from functional inactivation. Thus, DM not only functions of functional DR molecules by binding of fluorescently
labeled HA(307±319)peptide (HA) from influenza hemag-as a catalyst and peptide editor, but also serves as an
endosomal/lysosomal chaperone that keeps ab dimers glutinin (Jardetzky et al., 1990) in an assay based on high
performance size-exclusion chromatography (HPSEC)receptive for loading, thereby most likely increasing the
efficiency of antigen presentation along the class II (Kropshofer et al., 1995a). Preincubation for 15 min with-
out DM led to about 50% reduction in HA binding andpathway.
90% reduction after a 120 min preincubation period
compared with the situation without preincubation (Fig-Results
ure 1A). This is probably due to functional inactivation
of those DR1 dimers that have lost CLIP during theHLA-DM Specifically Stabilizes DR Molecules
in the Absence of Peptide preincubation interval. In contrast, when DR1±CLIP was
preincubated together with DM, DR1 molecules couldTo investigate whether DM regulates the loading pro-
cess beyond the stage of peptide release, we used af- be rescued in a dose-dependent manner (Figure 1A).
The inactivation of the DR1 molecules in the absencefinity-purified DM molecules and HLA-DR1 (DR1) from
DM-negative T2 transfectants. DR1 from T2 cells is of DM and peptide was irreversible, as those ab dimers
that had been inactivated during the preincubation pe-equivalent to a putative in vivo substrate of DM because
it is exclusively occupied by CLIP (data not shown). riod could not be rescued if DM was present for up to
120 min after the preincubation (Figure 1B).Given the rapid off-rate of CLIP at pH 5.0 in the detergent
Zwittergent-12, which enhances CLIP release (Krops- To evaluate the specificity of the DM effect, we in-
cluded other proteins in the assay. The protective effecthofer et al., 1995b) (half-maximal timet1¤2, off ≈ 15 min; data
not shown), 50% of the DR1 molecules are supposed to was also seen when DM was added together with an
irrelevant protein, bovine serum albumin (BSA), but BSAbe empty in the absence of peptide after 15 min incuba-
tion time. We therefore preincubated DR1±CLIP com- alone failed to preserve DR1 molecules (Figure 1C). Like-
wise, neither the murine class II molecule Ak nor theplexes for various time intervals with and without stoi-
chiometric amounts of DM and measured the availability monoclonal antibody (MAb) L243, which is known to
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Figure 2. DM Associates with DR Molecules
in the Absence of Peptide or the Presence of
Low Stability Peptides
(A) DR1±CLIP (50 nM) was coincubated with
the indicated peptides (50 mM) and DM (50
nM) for 2 hr at pH 5.0 and 378C, and immuno-
precipitations were carried out with the anti-
DMb MAb DM.K8 immobilized to Sepharose
beads. Immunoprecipitated material was an-
alyzed by SDS±PAGE and Western blotting.
Blots were probed with the anti-DRa MAb
1B5 (upper panel) and anti-DM MAb DM.K8
(lower panel).
(B) Half-lives of dissociation (t1¤2; off) of the indi-
cated AMCA-labeled peptides in the context
of DR1 were determined at pH 5.0 at 378C
as a measure of the kinetic stability of the
respective peptides, essentially as described
previously (Kropshofer et al., 1995a).
(C) DR1±CLIP complexes (100 nM) were pre-
incubated at pH 5.0 at 378C in the presence
and absence of DM (200 nM) for 60 min. CLIP
that has dissociated during this time was
quantitatively removed by extensively wash-
ing at pH 7.0 using ultrafiltration (5 kDa cut-
off). Peptides associated to the DR molecules
or DR±DM complexes were eluted with triflu-
oroacetic acid and analyzed by MALDI-MS.
As an internal reference peptide, 500 fmol of
synthetic Ii(183±193) from human Ii (se-
quence, EQKPTDAPPKE) was added to both
samples (indicated by R, m/z 5 1238.2) prior
to MALDI-MS analysis, so that both spectra
could be compared semiquantitatively.
bind to DR ab dimers (Lampson and Levy, 1980) even with the other peptides, does not detectably bind to
DR1 (Figure 2B). However, only small amounts of DRat pH 5 (data not shown), had any protective effect
(Figure 1C). molecules were recovered in the presence of stably
binding HA. Low amounts of DR1 bound to DM wereDM preserved the functionality of DR1 also when
probed with another peptide, the self-peptide DQSP also obtained if other peptides with high kinetic stability,
such as the self-peptide DQSP, had been added (Krops-derived from DQw6 (Vogt et al., 1994). During a 3 min
incubation time, efficient loadingof DR1 with DQSP pep- hofer et al., 1996; unpublished data). These results are
consistent with the view that DM preferentially binds totide was only obtained in the presence of DM (Figure
1D, lanes 1 and 2), emphasizing the catalytic power the cohort of empty ab dimers. This fraction is supposed
to be large if only peptides with low kinetic stability,of DM. However, when the DR1±CLIP complexes were
preincubated at pH 5.0 for 15 min and DQSP peptide such as MBP(87±99) or CLIP, are present, but small in
the presence of high stability peptides such as HA. Thisand DM were then added, the relative loading was re-
duced to about 35%. Again, preincubation together with correlation does not rule out that DM binds, at least for a
short period of time, to ab dimers loaded with peptides,DM prior to the addition of peptide completely restored
the ability of DR1 to be loaded afterwards (Figure 1D, such as CLIP.
To prove that DM±DR complexes were indeed emptylane 5). Together, these data suggest that after CLIP
release ab dimers can be kept functional by the specific after incubation at pH 5.0 without addition of peptides,
the complexes were separated from dissociated CLIP byassociation with DM.
ultrafiltration and acid extracted, and the eluted material
was analyzed by massspectrometry. As shown in FigureDM Remains Bound to Empty DR Molecules
A transient DM±DR interaction is likely to be sufficient 2C, (left panel), after a 60 min incubation in the absence
of DM a considerable amount of CLIP peptides couldfor the catalytic removal of CLIP or other peptide, but
a prolonged association between both molecules may be recovered. These CLIP peptides are derived from
those ab dimers that have not yet lost their CLIP and,be necessary for its protective function. Therefore, DR1±
CLIP complexes were coincubated with DM for 2 hr in most likely, also from those to which CLIP has rebound
during the 60 min incubation owing to its fast on-rate andthe absence and presence of peptides, immunoprecipi-
tated with the anti-DM MAb DM.K8, and probed for high affinity on DR1. These CLIP-bearing DR1 molecules
retained their capacity to exchange CLIP for HA (z25%;DR by Western blotting with the anti-DRa antibody 1B5
(Adams et al.,1983). Figure 2A shows that DR was copre- Figure 1A, left panel). In contrast, almost no CLIP pep-
tides could be recovered when DR1±CLIP complexescipitated with DM in the absence of added peptide as
well as in the presence of synthetic myelin basic protein had been coincubated with stoichiometric amounts of
DM (Figure 2C, right panel). We conclude that the DR1peptide (MBP(87±99)), CLIP(81±105), or the control pep-
tide CLIP(81±89) (Chicz et al., 1992), which, in contrast molecules bound to DM were empty and that DM itself
Immunity
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does not carry peptides, as verified by the mass spec-
trometry profile of DM alone (inset in Figure 2C, right
panel).
DM Reduces Aggregation of DR Molecules
Loss of functional class II molecules at low pH has been
reported to be accompanied by the formation of aggre-
gates (Stern and Wiley, 1992; Germain and Rinker, 1993).
We determined whether aggregation may also be a
cause for or a consequence of inactivation in the present
series of experiments. Again, a relatively short preincu-
bation time (15 min) was chosen because in cellular
loading compartments the majority of DR molecules are
not supposed to persist for prolonged periods of time
without encountering DM or peptide. Aggregated DR1
molecules were removed by centrifugation and quanti-
fied either indirectly by HPSEC analysis of the superna-
tant (Figure 3A, lower panel) or directly by Western blot
analysis of the pellet (Figure 3B). Upon decreasing the
pH of the preincubation medium from 5.5 to 3.0, an
increasing number of DR1 molecules lost their capacity
to bind HA (Figure 3A, upper panel, open bars). In paral-
lel, there was a growing percentage of aggregates (Fig-
ure 3A, lower panel; Figure 3B, upper panel). Addition
of DM reduced the degree of functional inactivation by
approximately 30%±50% in the pH range of 5.5±4.0 (Fig-
ure 3A, upper panel, closed bars), which is paralleled by
a correspondingreduction (60%±100%) in the amount of
aggregates (Figure 3A, lower panel). This effect is also
reflected by the Western blot analysis (Figure 3B, middle
panel): in the presence of DM there was no indication
of aggregated DR1 in the pelletabove pH 4.0. In addition,
Figure 3B shows that DM is also resistant to aggregation
above pH 4.0 (Figure 3B, lower panel). DM also prevents
DR1 from aggregation upon prolonged incubation (120
min) at pH 5.0, whereas this was not the case in the
presence of Ak, as demonstrated in Figure 3C. Further
experiments indicated that the tendency of DR1 to ag-
gregate is different in distinct detergents, but the protec-
tive effect of DM was observed in all detergents tested,
Figure 3. DM Prevents DR1 from Aggregation at Low pHas well as in detergent-free systems (data not shown).
(A) DR1±CLIP (100 nM) was preincubated for 15 min at the indicatedThus, in situations where the peptide supply is limited,
pH and 378C with and without DM (100 nM) under the same condi-DM may rescue empty class II molecules from aggrega- tions as described above and assayed for HA peptide binding. The
tion or denaturation in the low pH environment (around percentage of aggregates (Agg) was determined by measuring the
pH 5.0) of prelysosomes or lysosomes. absorbance at 214 nm of DR recovered prior to the incubation (A0)
and after incubation followed by centrifugation at 13,000 rpm for 5
min at 108C (At). For the calculation the following equation was used:DR Alleles Are Differentially Dependent Percent Agg 5 (A0 2 At)/A0 3 100.
on DM Stabilization (B) Western blot analysis of the pellet fraction obtained aftercentrifu-
gation as described above. Blots were probed for DR1 and DM withNext, we evaluated the role of DM in stabilizing empty
the MAbs 1B5 and DM.K8, respectively.ab dimers of different DR alleles (Figure 4). We found
(C) DR1 content of aggregates obtained after the indicated timethat DM preserved DR2a to a similar extent as DR1.
intervals in the absence of DM and in the presence of DM or Ak.Functional inactivation and protection by DM was not
Western blots were probed for DR1 with MAb 1B5.
a prerequisite of systems containing detergents, since
recombinant DM (Sloan et al., 1995) prolonged the sur-
vival of recombinant DR1 (Stern and Wiley, 1992) in a of empty DR3 ab dimers is likely to account for the
differential effects, in agreement with the reporteddetergent-free system to a similar extent as detergent-
solubilized DM protected intact DR1 (Figure 4). Interest- higher stability of DR3 in SDS compared with DR1 or
DR2a (Verreck et al., 1996). In the case of DR4, 50% ofingly, the DR3 allele was more resistant to functional
inactivation, as even a 1 hr preincubation reduced the the peptide-binding capacity was already lost after 3
min of preincubation, but was again rescued by DM.binding capacity by only 40% in the absence of DM.
Since DR1 and DR3 bind CLIP with comparable stabili- This argues in favor of a rather low intrinsic DR4 dimer
stability, consistent with previous findings (Devaux etties (Kropshofer et al., 1995b), a higher intrinsic stability
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Figure 4. Stabilization Effect of DM in the Context of Different DR
Alleles
Different allelic DR±CLIP complexes (50 nM) purified from the re-
spective T2 transfectants or recombinant sDR1 (50 nM) were prein-
cubated without peptide at pH 5.0 at 378C in the presence or ab-
sence of DM (50 nM) for the indicated period of time. The amount
of functional DR was quantified by HPSEC, as described for Figure
1A, by using AMCA-HA peptide for DR1, sDR1, DR2a, DR4, and
AMCA-HSP(3±13) for DR3. sDR1 purified from a baculo expression
system carried unstably bound, small peptides (data not shown)and
was analyzed in a detergent-free system, as described previously
(Kropshofer et al., 1995b), together with recombinant DM (Sloan et
al., 1995). DR4 molecules from T2 transfectants are occupied by a
considerable amount of non-CLIP peptides (data not shown) and
thus bind AMCA-HA less well, as already described for DR3 from
T2 cells (Kropshofer et al., 1995b). The following occupancies with
Figure 5. Sequential Percoll Gradient Fractionation of B Cell Organ-the respective AMCA peptides were attained: 13 6 2% for DR1;
elles and Membranes11% for sDR1; 14 6 3% for DR2; 3 6 1% for DR3; 4 6 1% for DR4.
(A) Distribution of the endocytic marker b-hexosaminidase (closed
diamonds) after an initial fractionation on a 25% Percoll gradient
and a consecutive separation of pooled high density fractions on aal., 1995). Thus, allelic DR products exhibit a differential
40% Percoll gradient (fractions 1±8) and of pooled low densitiydependency on DM, but all benefit from the stabilization
fractions on a 10% Percoll gradient (fractions 9±16). Fractions 1 andby DM.
9 correspond to the bottom of the 40% and the 10% gradient,
respectively.
DM Chaperones Empty Class II Molecules (B) Distribution of marker proteins lamp-1 (specific for lysosomes),
in Lysosomal Compartments CI-MPR (specific for late endosomes), and MHC class I molecules
(specific for ER, Golgi, and plasma membrane) compared with HLA-To explore the in vivo relevance of DM stabilizing empty
DR and HLA-DM in the organelle fractions separated by sequentialclass II molecules, we undertook a subcellular fraction-
Percoll gradient fractionation.ation of the B cell line WT-100 on two consecutive Per-
coll gradients and lysed the organelles in the mild deter-
gent CHAPS so that weak interactions remained intact. DR molecules that is engaged in long-lived DR±DM com-
plexes, we pooled the lysosomal organelles (fractionsThe sequential Percoll fractionation protocol allowed us
to separate three groups of compartments (Figure 5): a 1±8; Figure 5) and performed quantitative immunoblot-
ting for DM and DR using MAbs DM.K8 and 1B5, respec-mixture of ER, Golgi membranes, plasma membrane,
and early endosomes (fractions 13±16); late endosomes tively. The lysate was found to contain DM and DR in a
ratio of about 1:4 (130 mg of DM versus 500 mg of DR1;(fractions 9±12); and lysosomal organelles of different
densities (fractions 1±8) probably containing prelyso- Figure 6A). When anti-DM beads were used for affinity
purification and the isolated material was quantified bysomes and mature lysosomes, as well as MHC class II
compartments, MIICs (Sanderson et al., 1994, 1996). Western blotting, the relative amount of DR1 was about
25%±30% (40 mg of DR1 versus 130 mg of DM; FigureThis is substantiated by the distribution of the lysosomal
marker lamp-1 (lysosome-associated membrane pro- 6A). Subsequently, we purified most of the residual DR1
molecules (380 mg of DR1; Figure 6A) with the MAbtein 1) and the late endosomal marker CI-MPR (cation-
independent mannose-6-phosphate receptor) as shown L243, which recognizes DR molecules devoid of DM but
loaded with peptides (Figure 6C). Figure 6B shows anby Western blotting (Figure 5B), and by the activity pro-
file of b-hexosaminidase, an enzyme that is enriched in example of the quantitative immunoblotting of the DM±
class II complexes purified from the pooled fractionslysosomes and late endosomes (Castellino and Ger-
main, 1995). In contrast with MHC class I molecules, 1±8. Together these data indicate that in lysosomal com-
partments the ratio of DM:DR is about 1:4 and that aboutwhich are only found in low density fractions corre-
sponding to ER, Golgi, and plasma membrane, HLA- 8%±10% of the total number of DR1 molecules are en-
gaged in complexes with DM under steady-state condi-DR and HLA-DM cofractionate in most fractions of the
gradient, including late endosomal and lysosomal frac- tions. With regard to the approximate 1:20 DM:DR ratio
obtained in whole-cell lysates (Denzin and Cresswell,tions.
To demonstrate the existence of a subset of empty 1995; data not shown), our findings suggest that DM is
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Figure 6. Loading of Empty DM±Class II
Complexes from Lysosomal Compartments
(A) Amount of DR1 and DM in the lysate of
lysosomal compartments before affinity puri-
fication and amount of DR1 and DM isolated
by sequential affinity purification with anti-
DM MAb DM.K8 and anti-DR MAb L243. The
recoveries of DR1 and DM were quantified by
Western blotting, as described below.
(B) Aliquots (1 ml) of the DM±class II com-
plexes that were affinity purified from dense
organelles of WT-100 cells with the anti-DM
MAb DM.K8 were run on a 12% SDS gel to-
gether with a DM and a DR1 standard and
analyzed by quantitative Western blotting.
Staining with the anti-DRa MAb 1B5 and
comparison with titrations of purified DR1 re-
sulted in a signal intensity corresponding to
approximately 60 ng of purified DR1. Like-
wise, staining with the anti-DMb MAb DM.K8
gave a signal corresponding to approximately
180 ng of DM purified from T2.DR4.DM cells.
Lanes 2 and 3 show the signals obtained with
60 ng of DR1 and 180 ng of DM, respectively.
(C) DR1 (5 mg) and DM±class II complexes
(20 mg, containing approximately 5 mg of DR1
according to quantitative Western blotting)
were assayed for associated self-peptides by
acid release and mass spectrometry. R de-
notes the internal reference peptide EQKPT
DAPPKE. C1±C4 correspond to the CLIP
variants CLIP(82±102) (m/z 5 2334), CLIP (82±
103) (m/z 5 2431), CLIP(81±103) (m/z 5 2544),
and CLIP(81±104) (m/z 5 2675), respectively
(Kropshofer et al., 1995b).
(D) DM±class II complexes (equivalent of 100
nM DR1) or DR1 (100 nM) from lysosomal
compartments and DR1 (100 nM) from T2
cells together with DM (100 nM) were coincu-
bated for 3 min with AMCA-HA (10 mM) or
AMCA-HA/D309 (10 mM) as a negative control
and analyzed by HPSEC as described in the
legend of Figure 1A.
significantly enriched relative to DR molecules in the HLA-A2 (Chicz et al.,1992) to the lysosomal homogenate
prior to precipitation of DM±DR complexes, the amountmost acidic compartments of the endocytic pathway.
Acid elution and mass spectrometric analysis proved of DR1 coprecipitating with DM was reduced in both
cases, albeit to different extents (Figure 7). This was notthat the DM±class II complexes of lysosomal origin were
devoid of peptides (Figure 6C), confirming our in vitro the case when DM-sensitive peptides such as MBP(87±
99) or CLIP(81±105) were included. These data suggestfindings (see Figure 2C). In contrast, DR1 purified from
the same organelles by the MAb L243 (Figure 6A) gave that in loading compartments the supply of appropriate
self-peptides may be limiting and that empty class IIrise to a peptide profile consisting of a complex mixture
of self-peptides including a subset carrying CLIP (Figure molecules are chaperoned by DM.
6C), a pattern supposed to be characteristic of loading
compartments. The empty DR1 molecules in the purified Discussion
DM±DR1 complexes were fully functional, as they could
be rapidly loaded with the peptide antigen HA and to A set of universally conserved proteins has evolved,
collectively referred to as molecular chaperones, to dealthe same extent as DR1±CLIP complexes from T2 cells
supplemented with stoichiometric amounts of DM (Fig- with the problem of high protein concentration and po-
tential protein aggregation in all cellular compartmentsure 6D). In addition, DM±DR1 complexes showed the
same peptide binding specificity as DR1 molecules from (Ellis and van der Vies, 1991). Molecular chaperones
keep their substrate proteins in a particular conforma-T2 cells, since in both cases the control peptide, mutant
HA/D309, did not bind significantly. tion or state of folding so that protein aggregation is
minimized, thus ensuring proper formation or mainte-To address the question of whether in lysosomal or-
ganelles there is a lack of peptides appropriate for load- nance of tertiary or quaternary structures or transport
(or both).ing onto DR1 molecules, we probed with different syn-
thetic peptides. When we added DM-resistant peptides According to this definition, HLA-DM appears to qual-
ify as a chaperone: our results demonstrate that undersuch as HA or the self-peptide A2(103±120) (A2) from
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Moreover, our data provide a rationale for the pre-
viously reported coprecipitation of DM±DR3 complexes
by the conformation-specific MAb 16.23, which fails to
recognize DR3±CLIP complexes (Sanderson et al.,
1996). Most likely, in this particular experiment, MAb
16.23 recognized empty DR3 molecules stabilized by
DM. Prolonged binding of DM as a chaperone to un-
loaded class II molecules in vivo is in agreement with
recent pulse±chase experiments in which DM±DR com-
plexes survived for more than 10 hr (Denzin et al., 1996)
and explains why DM±DR complexes are stable enough
to withstand purification, which was not expected from
the transient nature of DM±class II interactions deducedFigure 7. Reduced Amount of DM±Class II Complexes in Lysosomal
from its function as a catalyst (Sloan et al., 1995; VogtCompartments upon Addition of High Stability Peptides
et al., 1996). Likewise, the catalytic role of DM alone mayCHAPS lysates of lysosomal compartments were adjusted to pH
not account for the dose effect on antigen presentation5.0, supplemented with the indicated peptides (50 mM), and incu-
observed in transfectants with different DM expressionbated for 30 min at 378C. After neutralization, DM±class II complexes
were immunoprecipitated with the anti-DMb MAb DM.K8 and ana- levels (Ramachandra et al., 1996). This in vivo finding is
lyzed by SDS±PAGE and Western blotting using the anti-DRa MAb reminiscent of the dose effect described in Figure 1A
IB5 (upper panel) and the anti-DMb MAb DM.K8 (lower panel). underlining the chaperone function of DM.
The novel role for DM described here could also ex-
conditions in which appropriate peptide is scarce, DM plain why DM proved to enhance antigen processing
binds to empty DR molecules in vitro (Figure 2) as well even in the context of alleles, such as Ak, where DM is
as in vivo (Figure 6), thereby preventing them from ag- not necessary for CLIP release (Brooks et al., 1994): on
gregation (Figure 3) and preserving their functionality the one hand, DM as a catalyst is able to accelerate the
(Figures 1, 6, and 7). The kinetics of functional inactiva- release of CLIP and Ii-derived intermediary LIP or SLIP
tion of DR1 (Figure 1A) appear to be faster than the fragments (Stebbins et al., 1996); on the other hand, DM
kinetics of aggregate formation (Figure 3C), supporting acting as a chaperone may preserve empty Ak molecules
the view that partial unfolding of class II molecules may until an appropriate peptide is available. This would also
precede aggregation in the absence of peptide. The ex explain the enhanced appearance of Ak at the surface of
vivo dataprove that in dense subcellular fractions, which spleen cells after pulsing with nominal antigen (Germain
probably contain lysosome-like MHC class II loading and Hendrix, 1991).
compartments, a considerable fraction of DR molecules Together, the observations suggest an important
(up to 10%) is associated with DM and devoid of pep- function of DM beyond the stage of CLIP removal and
tides. The relative abundance of peptides in loading strongly support the hypothesis that keeping class II
compartments has been a matter of debate. Germain molecules functional in vivo requires the transient asso-
ciation of chaperone molecules at all times after theirand Hendrix (1991) suggested that endosomal/lyso-
somal compartments are not saturated with self-pep- biosynthesis: in the ER, Golgi, and trans-Golgi network
Ii is responsible for preventing ab dimers from inefficienttides that fulfill the requirements for binding to MHC
class II molecules. Our findings extend these observa- assembly (Bikoff et al., 1993; Viville et al., 1993) and
subsequent loss due to aggregation (Marks et al.,tions by suggesting that the supply in particular of those
peptides that are resistant to DM-mediated removal is 1995a). Likewise, in Ii-deficient cells class II molecules
have been found in complexes with ER-resident chaper-limiting; otherwise we would not have been able to iso-
late empty DM±DR complexes whose amount was re- ones, such as GRP94 and ERp72 (Schaiff et al., 1992),
or stably associated with as yet undefined polypeptidesduced upon addition of high stability peptides such as
A2 or HA (Figure 7). The fact that HA reduced the amount (Busch et al., 1996). In acidic post-Golgi compartments,
Ii is successively degraded and, owing to the low kineticof DM bound to DR1 only slightly in lysosomal homoge-
nates (Figure 7), but strongly in the in vitro assay involv- stability of the residual Ii fragment CLIP, empty class
II±binding sites are created that have to be protecteding purified material (Figure 2A), might be due to a higher
susceptibility to residual proteolysis of HA compared by another chaperone, DM. Binding of DM seems to
be vital for ab dimers, especially in those endosomal/with A2 peptide during the 30 min incubation in the
lysosomal homogenate. lysosomal compartments where appropriate antigenic
polypeptide or peptide ligands are temporarily scarce.In accord with the necessity to stabilize empty class
II molecules in acidic loading compartments, we have In the absence of a stabilizing molecule, empty class II
ab dimers undergo denaturation and chain dissociation,observed that the amount of DM relative to DR is high
in lysosomal compartments (1:4) (Figure 5) compared whereupon they are prone to degradation (Germain and
Rinker, 1993). In contrast with Ii, DM is resistant to lowwith the ratio in whole cells (1:20) (Denzin and Cresswell,
1995). This is in agreement with a recent report in which pH and proteolytic attack and is able to associate with
any DR molecule that carries low stability peptides orDM was present in a molar ratio of 5 DR:1 DM in class
II peptide-loading compartments of another B cell line polypeptides, such as CLIP or LIP, respectively.
The structural basis for the chaperone activity of DM(Schafer et al., 1996). Likewise, in DM-negative T2.DR4
transfectants, considerably more DR aggregates could remains to be investigated. One might envisage at least
two ways in which DM could exert its chaperone func-be detected than in T2.DR4 cells transfected with DM
(unpublished data). tion: DM may either bind outside the class II±binding
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organelles with high density (1.05±1.07 g/ml)were pooled and refrac-groove, thereby preventing unfolding of empty ab di-
tionated on a 40% Percoll gradient. Similarly, fractions containingmers and concomitant exposure of hydrophobic regions
organelles and membranes of low density (,1.05 g/ml) were pooledso that aggregation of class II molecules is diminished;
and subfractionated on a 10% Percoll gradient. Prior to further anal-
alternatively, a certain portion of DM may mimic a pep- ysis, each fraction was separated from Percoll by 5-fold dilution
tide or polypeptide and bind, at least partially, into the with PBS and ultracentrifugation.
groove, but in a manner that does not prevent subse-
quent peptide uptake. Both possibilities are compatible Marker Analysis
with the concept that the catalytic (Vogt et al., 1996) The endocytic/lysosomal marker enzyme b-hexosaminidase (Mane
et al., 1989) was assayed by a published procedure (Green et al.,and the peptide editing function of DM (Sloan et al.,
1987). Lamp-1 (lysosomes; Mane et al., 1989), CI-MPR (trans-Golgi1995; Kropshofer et al., 1996; van Ham et al., 1996) are
network and late endosomes; Kornfeld, 1992), and MHC class Ibased on its chaperone activity, namely prolonging the
molecules HLA-A, HLA-B, and HLA-C (ER, Golgi, and plasma mem-
half-life of an otherwise short-lived transition state most brane; Tulpet al., 1994) were assayedby Western blotting. The rabbit
favorable for the initial docking of a peptide ligand anti-lamp-1 serum was a gift of Dr. Carlsson (Uppsala, Sweden).
(Kropshofer et al., 1997). The advantage of DM acting The anti-CI-MPR serum was a gift of Dr. von Figura (University of
GoÈ ttingen, FRG).Class I molecules weredetected by the anti±humanas a chaperone is that in situations in which the supply
class I heavy chain MAb HC-10 (Stam et al., 1990).of stably binding self-peptides is limiting, as appears
to be the case in lysosome-like loading compartments
Purification of Class II Moleculesdescribed here, new antigens entering the cell would not
HLA-DR molecules were isolated from the respective T2 transfec-necessarily have to compete with endogenous peptides
tants by affinity chromatography using anti-DR MAb L243, as de-
but would have a chance to be rapidly loaded onto those scribed (Kropshofer et al., 1995a). HLA-DM was affinity purified from
class II molecules that are kept empty and receptive human spleen using anti-DM MAb DM.K8 as described (Vogt et
by DM. al., 1996). HLA-DM±class II complexes and DR1 were purified from
pooled lysosomal fractions 1±9 of WT-100 cells, which were ob-
tained by Percoll density gradient centrifugation. Lysis and affinityExperimental Procedures
chromatography were performed as described for HLA-DM, except
that 1% (w/v) CHAPS (Sigma) was used as a detergent.Cells
The EBV-transformed homozygous B cell line WT-100 (DR1Dw1)
and the T 3 B hybrid cell line T2 transfected with the cDNA for either Peptide Binding Assay
DR1 (DRA1*0101/DRB1*0101) or DR2a (DRA1*0101/DRB5*0101), or Solubilized DR1 and the respective AMCA-labeled peptide were
DR3 (DRA1*0101/DRB1*0301) or DR4 (DRA1*0101/DRB1*0401), coincubated in the absence or presence of solubilized DM for vari-
were used as a source for the isolation of the respective DR allelic ous periods of time at 378C in 50 mM sodium phosphate, 50 mM
products. All cell lines were maintained in roller bottles at 378C by sodium citrate, 0.1% Zwittergent3-12 (pH 5.0) (Calbiochem, La Jolla,
culture in RPMI 1640 with HEPES (Life Technologies, Grand Island, CA). Binding was quantified by HPSEC, as described previously
NY) containing 10% heat-inactivated fetal calf serum (Konco Lab (Kropshofer et al., 1995a).
Division, Wiesbaden, Federal Republic of Germany [FRG]).
Mass Spectrometry
Peptides DR-associated peptides were analyzed by mass spectrometry as
Peptides were synthesized on an AMS422 multiple peptide synthe- described(Kropshofer et al., 1995b). In brief, 5±10mg of purified DR1,
sizer (Abimed, Langenfeld, FRG) using F-moc chemistry and were DM±DR1 complexes, or DM±class II complexes were extensively
purified by RP-HPLC. Purified peptides were analyzed by laser washed with aqua bidest. in an Ultrafree ultrafiltration tube with a
desorption mass spectrometry and shown to be single species.
5 kDa cutoff (Millipore). Peptides were eluted by incubation in 0.1%
N-terminal labeling with the fluorophor 7-amino-4-methylcoumarin-
trifluoroacetic acid (TFA) for 0.5 hr at 378C. After separationof protein
3-acetic acid (AMCA; Lambda, Graz, Austria) was performed as
by ultrafiltration, peptides were lyophilized and prepared for mass
described (Kropshofer et al., 1991). HA(307±319), PKYVKQNTLK
spectrometry by dissolution in 0.5 ml of 0.1% TFA and addition of
LAT, is derived from influenza virus hemagglutinin (Jardetzky et al.,
0.5 ml of 1,4-dihydroxybenzoic acid:acetonitrile (1:1). Spectra were
1990); MBP(87±99), VHFFKNIVTPRTP, is derived from human myelin
recorded on a Finnigan Lasermat and collected by averaging the
basic protein (Vogt et al., 1994); CLIP(81±105), LPKPPKPVSKMRMA ion signals from 20±50 individual laser shots.
TPLLMQALPMG, and CLIP(81±89), LPKPPKPVS, are derived from
human Ii (Kropshofer et al., 1995b); DQSP, DVGVYRAVTPQGRPDA,
Immunoprecipitationis a self-peptide derived from residues 43±58 of the human class II
After neutralization, in vitro or in vivo generated DR±DM complexesMHC molecule DQw6 (Vogt et al., 1994); A2(103±120), VGSDWRFLR
were immunoprecipitated with anti-DMb MAb DM.K8 coupled toGYHQYAYDG, is a self-peptide derived from the human MHC class
Sepharose beads. Incubation with beads was performed under rota-I molecule HLA-A2 (Chicz et al., 1992); HSP(3±13), KTIAYDEEARR,
tion for 4 hr at room temperature (purified molecules) or at 48Ccorresponds to the immunodominant epitope of Mycobacterium
(lysosomal lysate). The beads were then sedimented by centrifuga-tuberculosis (Geluk et al., 1992).
tion, the supernatant was removed, and the beads were extensively
washed with 100 mM sodium phosphate, 50 mM NaCl, 0.1% Zwitter-Antibodies
gent-12 (pH 7.0). Immunoprecipitates were eluted in Laemmli's sam-The hybridoma cell line L243 (anti-DRab; Lampson and Levy, 1980),
ple buffer and analyzed by Western blot analysis.1B5 (anti-DRa; Adams et al., 1983), and DM.K8 (anti-DMb; Krops-
hofer et al., 1996) have been described. For affinity chromatography
and immunoprecipitation with beads, L243and DM.K8 were coupled Western Blot Analysis
to CNBr-activated Sepharose CL-4B (Pharmacia, Upsala, Sweden) Samples were separated by SDS±polyacrylamide gel electrophore-
at a concentration of 3 mg of antibody per milliliter of gel. sis (SDS±PAGE) (12%) and transferred onto Immobilon PVDF mem-
branes (Millipore, Bedford, MA). Membranes were blocked in
blocking reagent (Boehringer, Mannheim, FRG). Antibody bindingSubcellular Fractionation
Cells (3 3 109) of the B-LCL WT-100 were subjected to sequential was detected by incubation with horseradish peroxidase±con-
jugated goat anti±mouse immunoglobulin (Dianova, Hamburg, FRG)Percoll density gradient centrifugation. The first step of the fraction-
ation, using 25% Percoll, was performed as described (Max et al., followed by enhanced chemiluminescence with Super-Signal
(Pierce, Rockford, IL).1993). To obtain a higher resolution, fractions containing lysosomal
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